Former VP, Medical Innovations, DH Diagnostics, LLC, Danaher corporate affiliate

Dr Egbuonu-Davis has broad strategic and operational experience in pharmaceuticals, public health, and consulting, including a track record of developing and implementing research, commercialization, and investment strategies for a variety of product and service innovations to enhance health and economic outcomes. Currently, Dr. Egbuonu-Davis serves on the boards of Phreesia (NYSE: PHR) a software as service company facilitating patient intake, payment processing and patient activation; Avanos Medical (NYSE: AVNS) a MedTech company with products for orthopedic pain and digestive health; and Omega Healthcare Investors (NYSE: OHI), a REIT focused on skilled nursing facilities. She is also a trustee for Johns Hopkins Medicine and provides advisory services though LED Enterprise LLC.

She has served in a variety of executive roles in biopharmaceuticals and diagnostics and has assessed and demonstrated value to support product acceptance by payers, providers, and patients. Most recently as Vice President, Medical Innovations for DH Diagnostics, LLC, a Danaher Corporation affiliate, she provided medical advice to influence research, partnership, and investment strategy across Danaher’s diagnostic platform businesses and led strategic initiatives for COVID 19 and Alzheimer’s. During this time, she also served as Interim Chief
Medical Officer for Danaher subsidiaries, Beckman Coulter, and Leica, creating processes to leverage medical expertise in product innovation, research, and development. Previously, at Sanofi, as Vice President, Global Patient Centered Outcomes and Solutions, she created patient
programs, services, and tools to enhance adherence and health outcomes in patients with chronic conditions. Earlier in her career, at Pfizer, she served as VP, US Medical Operations and VP of Global Outcomes Research and Medical Services, leading clinical and outcomes research departments, developing product value assessments in support of reimbursement and adoption, and influencing product investment and development decisions for an extensive product portfolio across a broad array of therapeutic areas. She has also served in strategic advisor roles for Avalere Health and Booz Allen, advising biopharmaceutical companies and trade associations on health care reform, technology assessment, quality metrics and incentives and implications for research and services.

She earned her Master of Business Administration in Health Care Management from Wharton School of the University of Pennsylvania, and she holds Doctor of Medicine and Master of Public Health (epidemiology) degrees from Johns Hopkins University, and is board certified in
pediatrics.